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ilieu Inte´rieur
he Search for
yocardial Arteriogenic Signals*
onald W. Millard, PHD,†
igang Wang, MD, PHD‡
incinnati, Ohio
laude Bernard, the father of modern physiology, applied
he scientific method to medicine and described the impor-
ance of context for physiological system functions. Bernard
oined the term “milieu intérieur” (1). Today we recognize
his physiological context and the intrinsic adaptive re-
ponses to maintain stable biological systems in response
o myriad physiological and pathological challenges as
homeostasis.”
See page 2141
An expert panel consensus report on arteriogenesis (2),
cknowledging Bernardian principles, concluded that:
) arteriogenesis is the preferred type of neovascularization
or purposes of restoring myocardial perfusion; 2) combina-
ion growth factor therapy or use of “master switch” genes
ay be optimal for clinically beneficial therapeutic angio-
enesis; 3) pre-clinical and clinical studies should be preceded
y tissue distribution studies to define the myocardial uptake
nd retention or expression of growth factor(s); and
) protein therapy is closer to practical use than is gene
herapy.
Coronary artery syndromes present homeostatic chal-
enges. Coronary arteriogenesis is considered to be tempo-
ally shaped by endogenous intramyocardial signaling mol-
cules. For the coronary circulation to keep pace with
athological processes (e.g., plaque formation, vasospastic
ehavior, adrenergic vasoconstriction) within the native
oronary arteries that eventually limit coronary flow and
ow reserve under times of increased cardiac demand (i.e.,
xercise), new coronary arterial vessel growth must match
losely the loss of native coronary artery capacity and flow
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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emodeling will result in myocardial ischemic injury and cell
eath.
The details of the myocardial “milieu interieur” that
enerates the expression of molecular signals for arteriogen-
sis in response to progressive coronary artery stenosis are
ncompletely understood. Heil et al. (3) distinguished be-
ween 2 important processes of coronary vascular growth:
) arteriogenesis is growth of pre-existing arterio-arterial
nastomoses induced by physical forces, most importantly
hear stress; whereas 2) angiogenesis is induced by hypoxia
nd results in new capillary growth. The potential for
daptive coronary collateral growth has been appreciated for
any years. Progressive coronary artery stenosis in the
orcine model amply illustrates the intrinsic capacity for
oronary artery collateral artery growth sufficient to support
iable myocardium (4). Native and adaptive coronary circu-
ation in humans and myriad other animals are documented
y Schaper (5) and Cohen (6).
With regard to coronary arteriogenesis, endothelial cells
ppear to orchestrate the response to ischemia (7) by sensing
hanges in fluid shear stress translated by bio-signals into an
ntegrated response. Integrins (8), tyrosine receptor kinases
9), G-protein coupled receptors (10), and ion channels (11)
ave each been proposed as endothelial cell membrane shear
tress sensors. Signal cascades initiated by fluid shear stress
hanges activate endothelial cells. Adhesion molecule (intra-
ellular adhesion molecule-1) and vascular cell adhesion
olecule-1 expression are up-regulated (12). Several chemo-
ines—tumor necrosis factor-alpha (13), granulocyte-
acrophage colony-stimulating factors (14), and granulocyte
olony-stimulating factor (15)—are increased, and nitric oxide
s released (16). These molecules establish a new “milieu
ntérieur” for coronary collateral growth.
In this issue of the Journal, Schirmer et al. (17) identify
ew bio-molecules correlated to human coronary collateral
evelopment. Their study implicates the chemokine (C-C
otif) ligand 11 (eotaxin-1) and macrophage migration
nhibitory factor in coronary arteriogenesis. These mole-
ules, emanating from the “milieu intérieur” of human heart
issue are postulated to participate in the complex interplay
f signals remodeling myocardium and coronary collaterals.
An important question arising from the outcomes and
peculations of this study is: Can arteriogenic or angiogenic
actor(s) improve cardiac pump function after scar is formed by
romoting myocardial neovascularization? This study pro-
ides no information on this. To date, clinical trials testing
ingle arteriogenic bio-molecules have demonstrated insuf-
cient efficacy or unacceptable side effects (18–20). Gene
ransfer from implanted cells has been shown to induce
yocardial angiogenesis (21) as has combination proteins—
broblast growth factor-2 with platelet-derived growth
actor BB (22). Enhancement of the intrinsic myocardial
tromal cell-derived factor can recruit pluripotent mesen-
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June 9, 2009:2148–9 Myocardial Arteriogenic Signalshymal stem cells to generate new cardiac myocytes and new
lood vessels (23).
Clinical trials (24) are currently exploring safety and
fficacy of: 1) bone marrow stem cells; 2) endothelial
rogenitor cells; 3) bicistronic vascular endothelial growth
actor-A 165/basic fibroblast growth factor plasmid; 4) gene
ransfer of vascular endothelial growth factor combined with
ral L-arginine supplementation; and 5) adenovirus
erotype-5 mediated fibroblast growth factor-4 gene trans-
er, among others.
Clinical studies such as that reported here by Schirmer
t al. (17), while presenting some surmountable limitations
coronary sampling rate and method, and fixed venous
ressure in coronary collateral flow index calculations), have
dentified new molecular signals possibly involved in coro-
ary arteriogenesis. Results from such studies may provide
mportant clues for future coronary arteriogenic therapies.
xperimental studies in models that reflect human coronary
ollateral biology will allow in situ tissue characterization of
elevant signaling molecules. Meanwhile, Schirmer et al.
25) continue expanding our understanding of arteriogenesis
nd its molecular signals.
Taken together, the search for myocardial signal mole-
ules that support arteriogenesis remains an active area of
nvestigation engaging basic research models, translational
fforts, and clinical trials. It is likely that time will reinforce
he Bernardian view that no one molecular entity or tech-
ological approach may be the “master switch” controlling
he molecular signaling cascade establishing a new “milieu
ntérieur” for arteriogenesis.
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31 Albert Sabin Way, P.O. Box 670575, Cincinnati, Ohio
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